SLG
CRL icon

Stanley-Laman Group’s Charles River Laboratories CRL Stock Holding History

Stanley-Laman Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,863
Closed -$2.59M – 282
2021
Q4 		$2.59M Buy
6,863
+151
+2% +$58.7K 0.3% 110
2021
Q3 		$2.77M Buy
+6,712
New +$2.79M 0.36% 72
2016
Q1 		– Sell
-10,448
Closed -$840K – 304
2015
Q4 		$840K Buy
+10,448
New +$754K 0.14% 164

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Stanley-Laman Group's CRL Position: Q1 2022 in Review

Stanley-Laman Group sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 6,863 shares — an estimated $2.59M sold.

Stanley-Laman Group first reported a position in CRL in Q4 2015 and held it in 3 quarters. The position peaked at $2.77M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Stanley-Laman Group reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Stanley-Laman Group sold 6,863 Charles River Laboratories shares in Q1 2022, an estimated $2.59M.
  • Stanley-Laman Group first reported a position in Charles River Laboratories in Q4 2015 and held it in 3 quarters.
  • Stanley-Laman Group's Charles River Laboratories position peaked at $2.77M in Q3 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Stanley-Laman Group's 13F filing for Q1 2022, filed 21 Apr 2022.